

Sample of cannabis CXBD cannabinoid related patents issued by parties trying to create drugs from cannabis primarily through synthetic and lab processes when much of the targeted benefits are available naturally and through natural extractions and separations which by themselves are not patentable - for example you likely cannot patent vitamin C, but perhaps you could patent a synthetic derivative or the process to create the synthetic variation. The illegality of cannabis protects much of this drug investment by pharmaceutical interests.

<b>PAT. NO.</b>	<b>Titl e</b>	<b>Title</b>
1	<a href="#">9,044,390</a>	<a href="#">Pharmaceutical composition and method of manufacturing</a>
2	<a href="#">9,035,130</a>	<a href="#">Reference plant, a method for its production, extracts obtained therefrom and their use</a>
3	<a href="#">9,034,395</a>	<a href="#">Processes and apparatus for extraction of active substances and enriched extracts from natural products</a>
4	<a href="#">9,029,423</a>	<a href="#">Pharmaceutical formulation</a>
5	<a href="#">9,023,322</a>	<a href="#">Chewing gum compositions comprising cannabinoids</a>
6	<a href="#">9,017,737</a>	<a href="#">Use of cannabinoids in combination with an anti-psychotic medicament</a>
7	<a href="#">9,006,269</a>	<a href="#">Azetidine derivatives</a>
8	<a href="#">8,987,312</a>	<a href="#">Alpha-keto heterocycles as FAAH inhibitors</a>
9	<a href="#">8,986,939</a>	<a href="#">Integrity testing of hair samples</a>
10	<a href="#">8,980,941</a>	<a href="#">Controlled Cannabis decarboxylation</a>
11	<a href="#">8,980,940</a>	<a href="#">Stable cannabinoid compositions and methods for making and storing them</a>
12	<a href="#">8,940,745</a>	<a href="#">Modulators of fatty acid amide hydrolase</a>
13	<a href="#">8,937,097</a>	<a href="#">Methods for purifying trans-(-)-.DELTA..sup.9-tetrahydrocannabinol and trans-(+)-.DELTA..sup.9-tetrahydrocannabinol</a>
14	<a href="#">8,933,197</a>	<a href="#">Compositions comprising modified biologically active polypeptides</a>
15	<a href="#">8,906,914</a>	<a href="#">Ethylene diamine modulators of fatty acid hydrolase</a>
16	<a href="#">8,901,111</a>	<a href="#">Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase</a>
17	<a href="#">8,895,078</a>	<a href="#">Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts</a>
18	<a href="#">8,877,769</a>	<a href="#">Heteroaryl-substituted urea modulators of fatty acid amide hydrolase</a>
19	<a href="#">8,859,016</a>	<a href="#">Sonically formed trichomic extract material</a>
20	<a href="#">8,853,263</a>	<a href="#">Co-therapy for the treatment of epilepsy and related disorders</a>
21	<a href="#">8,846,409</a>	<a href="#">Methods of preparing cannabinoids from plant material</a>
22	<a href="#">8,808,734</a>	<a href="#">Cannabinoid formulations</a>
23	<a href="#">8,790,719</a>	<a href="#">Phytocannabinoids in the treatment of cancer</a>
24	<a href="#">8,772,349</a>	<a href="#">Cannabinoid quinone derivatives</a>
25	<a href="#">8,771,760</a>	<a href="#">Method for the treatment of constipation</a>
26	<a href="#">8,758,826</a>	<a href="#">Cannabinoid receptor binding agents, compositions, and methods</a>

- 27 [8,735,374](#) **T** [Oral mucoadhesive dosage form](#)
- 28 [8,728,544](#) **T** [Sonically formed trichomic extract material](#)
- 29 [8,673,368](#) **T** [Cannabinoid-containing plant extracts as neuroprotective agents](#)
- 30 [8,642,645](#) **T** [Pharmaceutical composition comprising Cannabinoids](#)
- 31 [8,632,825](#) **T** [Anti-tumoural effects of cannabinoid combinations](#)
- 32 [8,629,275](#) **T** [AHCY hydrolase inhibitors for treatment of hyper homocysteinemia](#)
- 33 [8,629,177](#) **T** [Nanoencapsulated delta-9-tetrahydrocannabinol](#)
- 34 [8,628,796](#) **T** [Room-temperature stable dronabinol formulations](#)
- 35 [8,603,515](#) **T** [Pharmaceutical formulation](#)
- 36 [8,598,356](#) **T** [Heteroaryl-substituted urea modulators of fatty acid amide hydrolase](#)
- 37 [8,598,202](#) **T** [Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase](#)
- 38 [8,530,476](#) **T** [Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase](#)
- 39 [8,497,299](#) **T** [Compositions including quinonoid derivatives of cannabinoids for therapeutic use](#)
- 40 [8,481,085](#) **T** [Pharmaceutical compositions comprising cannabigerol](#)
- 41 [8,470,874](#) **T** [Pharmaceutical compositions comprising cannabichromene type compounds](#)
- 42 [8,461,159](#) **T** [Heteroaryl-substituted urea modulators of fatty acid amide hydrolase](#)
- 43 [8,450,346](#) **T** [Azetidines derivatives as FAAH inhibitors](#)
- 44 [8,449,908](#) **T** [Transdermal delivery of cannabidiol](#)
- 45 [8,445,034](#) **T** [Systems and methods for producing organic cannabis tincture](#)
- 46 [8,435,556](#) **T** [Transdermal delivery of cannabidiol](#)
- 47 [8,426,439](#) **T** [Compositions and methods for prophylaxis and treatment of addictions](#)
- 48 [8,410,064](#) **T** [Classical cannabinoid metabolites and methods of use thereof](#)
- 49 [8,383,842](#) **T** [Methods for purifying trans-\(-\)-.DELTA..sup.9-tetrahydrocannabinol and trans-\(+\)-.DELTA..sup.9-tetrahydrocannabinol](#)
- 50 [8,372,823](#) **T** [Tetracyclic inhibitors of fatty acid amide hydrolase](#)
-